- Home
- BEEM vs IFRX Comparison
BEEM vs IFRX Comparison
Compare BEEM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- IFRX
- Stock Information
- Founded
- BEEM 2006
- IFRX 2007
- Country
- BEEM United States
- IFRX Germany
- Employees
- BEEM N/A
- IFRX N/A
- Industry
- BEEM Semiconductors
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- IFRX Health Care
- Exchange
- BEEM Nasdaq
- IFRX Nasdaq
- Market Cap
- BEEM 48.4M
- IFRX 53.5M
- IPO Year
- BEEM N/A
- IFRX 2017
- Fundamental
- Price
- BEEM $2.98
- IFRX $1.58
- Analyst Decision
- BEEM Strong Buy
- IFRX Strong Buy
- Analyst Count
- BEEM 4
- IFRX 5
- Target Price
- BEEM $5.33
- IFRX $7.40
- AVG Volume (30 Days)
- BEEM 2.0M
- IFRX 536.6K
- Earning Date
- BEEM 11-13-2025
- IFRX 11-07-2025
- Dividend Yield
- BEEM N/A
- IFRX N/A
- EPS Growth
- BEEM N/A
- IFRX N/A
- EPS
- BEEM N/A
- IFRX N/A
- Revenue
- BEEM $33,362,000.00
- IFRX $191,224.00
- Revenue This Year
- BEEM N/A
- IFRX N/A
- Revenue Next Year
- BEEM $45.38
- IFRX $1,216.24
- P/E Ratio
- BEEM N/A
- IFRX N/A
- Revenue Growth
- BEEM N/A
- IFRX 54.36
- 52 Week Low
- BEEM $1.33
- IFRX $0.71
- 52 Week High
- BEEM $5.31
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- BEEM 59.19
- IFRX 64.75
- Support Level
- BEEM $2.82
- IFRX $1.29
- Resistance Level
- BEEM $2.96
- IFRX $1.44
- Average True Range (ATR)
- BEEM 0.24
- IFRX 0.14
- MACD
- BEEM 0.02
- IFRX 0.00
- Stochastic Oscillator
- BEEM 71.08
- IFRX 90.74
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.